balsalazide

(redirected from Balsalazide disodium)
Also found in: Wikipedia.

balsalazide

 [bal-sal´ah-zīd]
a prodrug of the antiinflammatory mesalamine, to which it is converted in the colon; administered orally as the disodium salt in the treatment of ulcerative colitis.

balsalazide

/bal·sal·a·zide/ (bal-sal´ah-zīd) a prodrug of the antiinflammatory mesalamine, to which it is converted in the colon; administered orally as the sodium salt in the treatment of ulcerative colitis.

balsalazide

[bal-sal′ah-zīd]
a prodrug of the antiinflammatory mesalamine, to which it is converted in the colon; administered orally as the disodium salt in the treatment of ulcerative colitis.

balsalazide

Colazal® Internal medicine An agent that delivers concentrated 5-aminosalicylic acid to the colonic mucosa in Pts with ulcerative colitis. See Ulcerative colitis.

balsalazide

A drug used in the treatment of ULCERATIVE COLITIS. A brand name is Colazide.
Mentioned in ?
References in periodicals archive ?
Results showed that after 12 months of therapy for continuing patients, 20 percent of Lialda patients were continually persistent, 9 percent of Asacol(R) (mesalamine) patients, 7 percent (250mg) and 10 percent (500mg) of Pentasa(R) (mesalamine) patients, 10 percent of balsalazide [combined results from generic balsalazide disodium and Colazal(R) (balsalazide disodium)] patients, and 10 percent (500mg) of Dipentum(R) (olsalazine sodium) patients were persistent.
announced today the approval of its Abbreviated New Drug Application (ANDA) for Balsalazide Disodium Capsules, 750mg by the U.
Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Balsalazide Disodium Capsules, 750 mg.
Salix submitted a New Drug Application to the FDA on July 17, 2007 seeking approval to market an 1100 mg tablet formulation of balsalazide disodium (balsalazide tablet) for the treatment of mildly to moderately active ulcerative colitis.
Balsalazide disodium was first approved, under the tradename Colazide(R), by the United Kingdom Medicines Control Agency in July 1997 as a treatment for acute ulcerative colitis and has since also been approved for use in the maintenance of remission of ulcerative colitis.
Salix's lead product is balsalazide disodium, a treatment for ulcerative colitis.
Balsalazide disodium has also been approved for sale in Argentina, Austria, Belgium, Brazil, Czech Republic, Denmark, Iceland, Italy, Luxembourg, Norway, Sweden and Switzerland.
Salix submitted a New Drug Application (NDA) to the United States FDA for the use of balsalazide disodium as a treatment for acute ulcerative colitis and received an approvable letter from the FDA in June 1998.
The FDA indicated that the submission by Salix was considered a complete response to the ``approvable'' letter for balsalazide disodium.
The Company submitted a New Drug Application (NDA) to the United States FDA for the use of balsalazide disodium as a treatment for acute ulcerative colitis and received an approvable letter from the FDA in June 1998.
The Company submitted a New Drug Application (NDA) to the FDA for the use of balsalazide disodium for the same indication and received an approvable letter from the FDA in June 1998.
The Company submitted a New Drug Application (NDA) to the FDA for the use of balsalazide disodium (Colazide) for the same indication and received an approvable letter from the FDA in June 1998.